+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Patient-Derived Xenograft/PDX Model Market by Type (Mice Models, Rat Models), Tumor Type (Gastrointestinal, Gynecological, Hematological), Study Type, Implantation Method, Application, End-User - Global Forecast 2025-2030- Product Image
Patient-Derived Xenograft/PDX Model Market by Type (Mice Models, Rat Models), Tumor Type (Gastrointestinal, Gynecological, Hematological), Study Type, Implantation Method, Application, End-User - Global Forecast 2025-2030- Product Image
Sale

Patient-Derived Xenograft/PDX Model Market by Type (Mice Models, Rat Models), Tumor Type (Gastrointestinal, Gynecological, Hematological), Study Type, Implantation Method, Application, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 195 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5637019
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The patient-derived xenograft (PDX) model market is rapidly evolving as a preferred approach in translational oncology, providing senior decision-makers in research and drug development with reliable in-vivo platforms for assessing cancer therapies.

Market Snapshot: Patient-Derived Xenograft/PDX Model Market

The Patient-Derived Xenograft/PDX Model Market grew from USD 429.04 million in 2024 to USD 480.65 million in 2025. It is expected to continue growing at a CAGR of 12.33%, reaching USD 862.31 million by 2030.

Scope & Segmentation

This report delivers comprehensive segmentation analysis, mapping out current demand patterns and market drivers:

  • Type: Mice Models, Rat Models
  • Tumor Type: Gastrointestinal, Gynecological, Hematological, Respiratory, Urological
  • Study Type: Ex-vivo, In-vitro, In-vivo
  • Implantation Method: Heterotopic, Orthotopic, Subcutaneous
  • Application: Basic Cancer Research, Biomarker Discovery, Genomic & Molecular Studies, Personalized Medicine, Preclinical Drug Evaluation, Tumor Microenvironment Analysis
  • End-User: Academic Research Institutes, Cancer Research Centers, Pharmaceutical & Biotechnology Companies
  • Region: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Saudi Arabia, South Africa, and more), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, and others)
  • Key Technologies: Genome editing, intravital microscopy, digital pathology, high-throughput screening, humanized mouse models, advanced imaging, molecular profiling, bioinformatics
  • Major Companies: Includes Abnova Corporation, Altogen Labs, Biocytogen, BioDuro LLC, Charles River Laboratories International, Inc., Crown Bioscience by JSR Corporation, Laboratory Corporation of America Holdings, WuXi AppTec Co., Ltd., and others

Key Takeaways for Senior Decision-Makers

  • Integration of molecular profiling and bioinformatics is enhancing the precision and applicability of PDX models in therapeutic research and personalized medicine approaches.
  • Market adoption is driven by advancements in engraftment techniques, imaging platforms, and protocol standardization, resulting in improved model reliability across research and clinical pipelines.
  • Regional demand is shaped by funding ecosystems, contract research infrastructure, and localized manufacturing which support agile responses to regulatory and supply challenges.
  • Research segmentation increasingly distinguishes by cancer type, experimental methodology, and end-user application, allowing for tailored solutions and efficient resource deployment.
  • Partnerships between model providers and genomic data platforms support streamlined study design, improved candidate selection, and optimized clinical development pathways.
  • Diversification toward localized production and expanded contract breeding partnerships enhances resilience in the face of market disruptions.

United States Tariff Impact on Supply Chain

Recent tariff introductions in the United States have increased costs for laboratory supplies, feed, and equipment essential for PDX production. Vendors are responding by reassessing sourcing, optimizing logistics, and partnering with domestic breeders to ensure continuity and stability in supply chains. These supply chain adjustments have altered procurement and operational approaches for both providers and clients, with long-term trends favoring regionalization and cost management.

Methodology & Data Sources

Insights are derived from a rigorous methodology that combines secondary data analysis with primary expert interviews. Market mapping leveraged academic publications, patent filings, supplier portfolios, and direct engagement with industry experts to ensure accuracy and relevance.

Why This Report Matters

  • Supports strategic investments by clarifying evolving market trends and regional adoption patterns in the patient-derived xenograft model sector.
  • Enables informed procurement and partnership planning through a detailed understanding of segmentation, technology deployment, and supply chain dynamics.
  • Provides senior leaders with actionable intelligence for navigating regulatory shifts, optimizing operational models, and maximizing R&D value.

Conclusion

Patient-derived xenograft models are central to advancing precision oncology and therapeutic development. Enhanced integration, regional agility, and collaboration will shape ongoing innovation, keeping these platforms essential for future cancer research breakthroughs.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of humanized immune system mice in PDX models to optimize immunotherapy responses
5.2. Application of CRISPR gene editing in PDX models to accelerate personalized oncology drug screening
5.3. Adoption of high-throughput automated PDX platforms for large-scale preclinical drug evaluation
5.4. Collaboration between biopharma and CROs to standardize PDX model quality control and reproducibility
5.5. Development of organoid-derived xenograft models to complement PDX studies in heterogenous tumors
5.6. Use of multi-omics profiling in PDX models to identify predictive biomarkers for targeted therapies
5.7. Expansion of PDX biobank repositories with diverse ethnic and rare cancer subtypes for global research access
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Patient-Derived Xenograft/PDX Model Market, by Type
8.1. Introduction
8.2. Mice Models
8.3. Rat Models
9. Patient-Derived Xenograft/PDX Model Market, by Tumor Type
9.1. Introduction
9.2. Gastrointestinal
9.3. Gynecological
9.4. Hematological
9.5. Respiratory
9.6. Urological
10. Patient-Derived Xenograft/PDX Model Market, by Study Type
10.1. Introduction
10.2. Ex-vivo
10.3. In-vitro
10.4. In-vivo
11. Patient-Derived Xenograft/PDX Model Market, by Implantation Method
11.1. Introduction
11.2. Heterotopic
11.3. Orthotopic
11.4. Subcutaneous
12. Patient-Derived Xenograft/PDX Model Market, by Application
12.1. Introduction
12.2. Basic Cancer Research
12.3. Biomarker Discovery
12.4. Genomic & Molecular Studies
12.5. Personalized Medicine
12.6. Preclinical Drug Evaluation
12.7. Tumor Microenvironment Analysis
13. Patient-Derived Xenograft/PDX Model Market, by End-User
13.1. Introduction
13.2. Academic Research Institutes
13.3. Cancer Research Centers
13.4. Pharmaceutical & Biotechnology Companies
14. Americas Patient-Derived Xenograft/PDX Model Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Patient-Derived Xenograft/PDX Model Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Patient-Derived Xenograft/PDX Model Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Abnova Corporation
17.3.2. Altogen Labs
17.3.3. Biocytogen
17.3.4. BioDuro LLC
17.3.5. BioReperia AB
17.3.6. Certis Oncology Solutions
17.3.7. Champions Oncology, Inc.
17.3.8. Charles River Laboratories International, Inc.
17.3.9. Creative Animodel
17.3.10. Creative Biolabs
17.3.11. Crown Bioscience by JSR Corporation
17.3.12. EPO Berlin-Buch GmbH
17.3.13. GemPharmatech Co. Ltd.
17.3.14. Genesis Drug Discovery & Development
17.3.15. Hera Biolabs
17.3.16. HOIST Co.,Ltd.
17.3.17. InnoSer
17.3.18. Inotiv, Inc.
17.3.19. Laboratory Corporation of America Holdings
17.3.20. LIDE Shanghai Biotech, Ltd
17.3.21. Mediford Corporation by PHC Holdings Corporation
17.3.22. Oncodesign Services
17.3.23. Shanghai ChemPartner
17.3.24. Shanghai Medicilon Inc.
17.3.25. TheraIndx Lifesciences Pvt. Ltd.
17.3.26. Urosphere SAS
17.3.27. WuXi AppTec Co., Ltd.
17.3.28. Xentech
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET: RESEARCHAI
FIGURE 28. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET: RESEARCHSTATISTICS
FIGURE 29. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET: RESEARCHCONTACTS
FIGURE 30. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 93. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 94. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 95. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 96. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 97. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
TABLE 98. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2030 (USD MILLION)
TABLE 99. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
TABLE 100. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2030 (USD MILLION)
TABLE 101. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 102. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 103. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 104. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 105. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 106. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 107. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 108. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 109. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
TABLE 110. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2030 (USD MILLION)
TABLE 111. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
TABLE 112. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2030 (USD MILLION)
TABLE 113. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 114. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 115. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 116. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2030 (USD MILLION)
TABLE 123. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
TABLE 124. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2030 (USD MILLION)
TABLE 125. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 126. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2030 (USD MILLION)
TABLE 135. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
TABLE 136. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2030 (USD MILLION)
TABLE 137. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 138. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 139. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 140. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 156. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 158. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
TABLE 160. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
TABLE 162. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 164. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 166. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 167. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 168. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 169. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 170. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 171. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
TABLE 172. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2030 (USD MILLION)
TABLE 173. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
TABLE 174. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2030 (USD MILLION)
TABLE 175. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 176. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 177. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 178. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 179. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 180. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 181. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 182. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 183. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
TABLE 184. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2030 (USD MILLION)
TABLE 185. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
TABLE 186. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2030 (USD MILLION)
TABLE 187. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 188. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 189. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 190. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 191. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 192. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 193. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 194. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 195. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
TABLE 196. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2030 (USD MILLION)
TABLE 197. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
TABLE 198. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2030 (USD MILLION)
TABLE 199. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 200. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 201. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 202. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 203. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 204. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 205. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 206. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 207. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
TABLE 208. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2030 (USD MILLION)
TABLE 209. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
TABLE 210. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2030 (USD MILLION)
TABLE 211. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 212. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 213. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 214. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 215. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 216. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 217. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 218. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 219. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
TABLE 220. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2030 (USD MILLION)
TABLE 221. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
TABLE 222. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2030 (USD MILLION)
TABLE 223. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 224. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 225. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 226. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 238. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 240. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 242. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
TABLE 244. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
TABLE 246. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 248. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 250. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 252. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 254. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
TABLE 256. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2030 (USD MILLION)
TABLE 257. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
TABLE 258. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2030 (USD MILLION)
TABLE 259. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 260. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 261. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 262. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 263. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 264. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 265. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 266. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 267. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
TABLE 268. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2030 (USD MILLION)
TABLE 269. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
TABLE 270. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2030 (USD MILLION)
TABLE 271. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 272. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 273. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 274. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 275. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 276. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 277. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 278. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 279. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
TABLE 280. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2030 (USD MILLION)
TABLE 281. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
TABLE 282. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2030 (USD MILLION)
TABLE 283. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 284. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 285. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 286. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 287. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 288. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 289. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 290. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 291. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
TABLE 292. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2030 (USD MILLION)
TABLE 293. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
TABLE 294. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2030 (USD MILLION)
TABLE 295. QATAR PATIENT-DERIVED XENOGRAFT/P

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Patient-Derived Xenograft/PDX Model market report include:
  • Abnova Corporation
  • Altogen Labs
  • Biocytogen
  • BioDuro LLC
  • BioReperia AB
  • Certis Oncology Solutions
  • Champions Oncology, Inc.
  • Charles River Laboratories International, Inc.
  • Creative Animodel
  • Creative Biolabs
  • Crown Bioscience by JSR Corporation
  • EPO Berlin-Buch GmbH
  • GemPharmatech Co. Ltd.
  • Genesis Drug Discovery & Development
  • Hera Biolabs
  • HOIST Co.,Ltd.
  • InnoSer
  • Inotiv, Inc.
  • Laboratory Corporation of America Holdings
  • LIDE Shanghai Biotech, Ltd
  • Mediford Corporation by PHC Holdings Corporation
  • Oncodesign Services
  • Shanghai ChemPartner
  • Shanghai Medicilon Inc.
  • TheraIndx Lifesciences Pvt. Ltd.
  • Urosphere SAS
  • WuXi AppTec Co., Ltd.
  • Xentech

Table Information

Report AttributeDetails
No. of Pages195
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 480.65 Million
Forecasted Market Value ( USD ) by 2030 $ 862.31 Million
Compound Annual Growth Rate12.3%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

Patient Derived Xenograft (PDX) Models Market Report 2025 - Product Image

Patient Derived Xenograft (PDX) Models Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Patient Derived Xenograft / PDX Models - Global Strategic Business Report - Product Image

Patient Derived Xenograft / PDX Models - Global Strategic Business Report

  • Report
  • 310 Pages
  • Global
From
Patient-Derived Xenograft Model Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Patient-Derived Xenograft Model Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Patient-derived Xenograft Model Market Size, Share & Trends Analysis Report By Tumor Type (Lung Cancer, Breast Cancer), By Model Type (Mice Model, Rat Model), By End Use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Patient-derived Xenograft Model Market Size, Share & Trends Analysis Report By Tumor Type (Lung Cancer, Breast Cancer), By Model Type (Mice Model, Rat Model), By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Oncology Based in-Vivo CRO Market Report by Indication, Model, Application, and Region 2025-2033 - Product Image

Oncology Based in-Vivo CRO Market Report by Indication, Model, Application, and Region 2025-2033

  • Report
  • 148 Pages
  • Global
From

About the Patient Derived Xenograft Market

The Patient Derived Xenograft (PDX) market is a rapidly growing segment of the drug discovery industry. PDX models are derived from human tumors that are implanted into immunodeficient mice, allowing researchers to study the effects of drugs on human cancer in a living system. PDX models are used to identify new drug targets, evaluate drug efficacy, and assess drug safety. They are also used to study the biology of cancer and to develop personalized treatments. PDX models are increasingly being used in clinical trials to evaluate the efficacy of new drugs. PDX models offer several advantages over traditional cell-based models, including the ability to study the effects of drugs on a living system, the ability to study the effects of drugs on multiple tumor types, and the ability to study the effects of drugs on the tumor microenvironment. Companies in the PDX market include Charles River Laboratories, Crown Bioscience, Horizon Discovery, and Taconic Biosciences. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.